A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan

Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children

(2012) Gabriel J. Robbie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study

(2011) Jon P. Fryzek et al.   ADVANCES IN THERAPY

Epidemiological Study of Hospitalization Associated With Respiratory Syncytial Virus Infection in Taiwanese Children Between 2004 and 2007

(2011) Hsin Chi et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Commentary: Why Are Young Healthy Term Infants Protected Against Respiratory Syncytial Virus Bronchiolitis?

(2011) Louis Bont et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

CARESS: The Canadian Registry of Palivizumab

(2011) Ian Mitchell et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Burden of Respiratory Syncytial Virus Infection in Young Children

(2009) Caroline Breese Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections

(2009)   PEDIATRICS

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

(2008) M Frogel et al.   Journal of Perinatology

Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score

(2008) Peter C. Austin   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY